Join
Live feed
·
PRReleasevia Quantisnow
Kiniksa Pharmaceuticals International plc logo

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

ByQuantisnow·Wall Street's wire, on your screen.
KNSA· Kiniksa Pharmaceuticals International plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KNSA (Kiniksa Pharmaceuticals International plc) and more on Quantisnow.